Fig 1: Hesperidin protected intestinal barrier integrity in HFD-fed mice. ND- and HFD-fed mice were treated every other day with 100 mg/kg BW or 200mg/kg BW by intragastric gavage for 6 weeks (n=6 for each group). (A) Colon length. (B) Levels of lipid binding protein (LBP) in plasma. (C) Levels of intestinal fatty acid binding protein (iFABP) in plasma. (D) Relative mRNA levels of Muc2 in colon. (E) Relative mRNA levels of claudin 2 in colon. (F) Relative mRNA levels of occludin in colon. (G) Relative mRNA levels of ZO-1 in colon. Data are expressed as mean ± SEM. All differences were analyzed using unpaired two-tailed Student’s t-test (*P<0.05, **P<0.01, ***P<0.001).
Fig 2: Obesity, inflammation and Intestinal barrier dysfunction were partly reversed by FMT from donor to recipient mice. (A) ND- and HFD-fed mice were treated every other day with either saline or fecal bacteria (300 mg/kgBW) from donor mice by intragastric gavage for 6 weeks (n=6 for each group). (B) body weight gain. (C) Epididymal fat. (D) Mesenteric fat. (E) Plasma levels of TNF-α. (F) Plasma levels of IL-6. (G) Relative mRNA levels of TNF-α in colon. (H) Relative mRNA levels of IL-6 in colon. (I) Relative mRNA levels of IL-1β in colon. (J) Relative mRNA levels of iNOS in colon. (K) Colon length. (L) Plasma levels of lipid binding protein(LBP) (M) Plasma levels of intestinal fatty acid binding protein (iFABP). Data are expressed as mean ± SEM. All differences were analyzed using unpaired two-tailed Student’s t-test (*P<0.05, **P<0.01).
Fig 3: Hesperidin protected intestinal barrier integrity in HFD-fed mice. ND- and HFD-fed mice were treated every other day with 100 mg/kg BW or 200mg/kg BW by intragastric gavage for 6 weeks (n=6 for each group). (A) Colon length. (B) Levels of lipid binding protein (LBP) in plasma. (C) Levels of intestinal fatty acid binding protein (iFABP) in plasma. (D) Relative mRNA levels of Muc2 in colon. (E) Relative mRNA levels of claudin 2 in colon. (F) Relative mRNA levels of occludin in colon. (G) Relative mRNA levels of ZO-1 in colon. Data are expressed as mean ± SEM. All differences were analyzed using unpaired two-tailed Student’s t-test (*P<0.05, **P<0.01, ***P<0.001).
Fig 4: Obesity, inflammation and Intestinal barrier dysfunction were partly reversed by FMT from donor to recipient mice. (A) ND- and HFD-fed mice were treated every other day with either saline or fecal bacteria (300 mg/kgBW) from donor mice by intragastric gavage for 6 weeks (n=6 for each group). (B) body weight gain. (C) Epididymal fat. (D) Mesenteric fat. (E) Plasma levels of TNF-α. (F) Plasma levels of IL-6. (G) Relative mRNA levels of TNF-α in colon. (H) Relative mRNA levels of IL-6 in colon. (I) Relative mRNA levels of IL-1β in colon. (J) Relative mRNA levels of iNOS in colon. (K) Colon length. (L) Plasma levels of lipid binding protein(LBP) (M) Plasma levels of intestinal fatty acid binding protein (iFABP). Data are expressed as mean ± SEM. All differences were analyzed using unpaired two-tailed Student’s t-test (*P<0.05, **P<0.01).
Supplier Page from CUSABIO Technology LLC for Mouse Lipopolysaccharide-binding protein(LBP) ELISA Kit